A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suit

Net profit soared by 110%! This CRO hidden champion can no longer be concealed

Chemexpress's net profit is expected to grow by 62.5% year-on-year in 2024, with the growth rate in the first half of the year soaring to 111.4%. The company's stock price has more than doubled in the past year, and it has reached a strategic cooperation agreement with Mabwell and InSilico Medicine Cayman TopCo to jointly develop a new ADC compound library. After experiencing an investment winter, the CRO industry is reshaping its ecosystem as the research and development of innovative drugs warms up

The concept of innovative drugs has risen again, with Chemexpress up over 15%

The concept of innovative drugs has risen again, with Chemexpress up over 15%, and Konruns and huahaipharm hitting the daily limit

A-share innovative drug concept stocks rose again, with Chemexpress, HitGen, and Medicilon increasing by over 10%, while Bide and WuXi AppTec also followed suit

Chemexpress: Net profit in the first half of 2025 increased by 115.55% year-on-year

Chemexpress announced that in the first half of 2025, the operating revenue was 1.311 billion yuan, a year-on-year increase of 24.20%. The net profit was 152 million yuan, a year-on-year increase of 115.55%. The company plans to distribute a cash dividend of 0.80 yuan for every 10 shares to all shareholders, with a total cash dividend distribution amounting to 16.9679 million yuan, accounting for 11.18% of the net profit attributable to the shareholders of the listed company for the first half of 2025